Key Points
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter.
The quarter-end position value increased by $5.79 million as a result of the transaction.
This marked a new position for Sarissa.
- 10 stocks we like better than Biohaven ›
Sarissa Capital Management established a new position in Biohaven Ltd. (NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing.
What happened
According to an SEC filing dated February 17, 2026, Sarissa Capital Management initiated a new stake in Biohaven during the fourth quarter, purchasing 513,184 shares. The quarter-end valuation of the new position stood at $5.79 million, reflecting the total value of shares held after the trade.
What else to know
- This was a new position for Sarissa, bringing Biohaven Ltd. to 2.6% of reportable U.S. equity AUM.
- Top holdings after the filing:
- NASDAQ:INVA: $56.29 million (25.3% of AUM)
- NASDAQ:IRWD: $53.65 million (24.1% of AUM)
- NASDAQ:NBIX: $43.00 million (19.3% of AUM)
- NASDAQ:CYTK: $25.18 million (11.3% of AUM)
- NASDAQ:AMRN: $23.35 million (10.5% of AUM)
- As of Monday, Biohaven shares were priced at $8.90, down a staggering 70% over the past year and well underperforming the S&P 500, which is instead up about 15% in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of Monday) | $8.90 |
| Market Capitalization | $1.3 billion |
| Net Income (TTM) | ($738.8 million) |
Company snapshot
- Biohaven develops therapies for neurological and immunoscience diseases; currently focused on clinical-stage drug candidates.
- The firm operates a biopharmaceutical business model centered on research and development, with future revenue expected from licensing and commercialization of proprietary treatments.
- It targets healthcare providers and patients affected by neurological and immune-related conditions as primary customers.
Biohaven Ltd. is a clinical-stage biotechnology company specializing in the development of innovative therapies for neurological and immunoscience disorders. With a focus on advancing novel drug candidates, the company leverages proprietary research to address unmet medical needs. Biohaven aims to establish a competitive position through its commitment to scientific innovation and targeted therapeutic development.
What this transaction means for investors
Biohaven today is a reset story. The FDA rejection of troriluzole and a string of disappointing trial updates crushed sentiment, but the underlying strategy hasn’t disappeared. Management is now concentrating resources on a smaller set of late-stage programs, including its degrader platform and a Phase 2 obesity candidate with data expected later this year. That kind of focus matters when capital is tight.
The balance sheet is still holding up better than you might expect for a company in this position. Biohaven ended 2025 with roughly $322 million in cash and raised another $178.9 million after year-end, buying it time to get through key clinical readouts. Meanwhile, its obesity program just completed enrollment, setting up a potential catalyst in the second half of 2026 .
Put this in context of the portfolio, and the logic becomes clearer. This is a fund that already leans heavily into clinical-stage biotech, so adding a distressed name fits the playbook. Upcoming data and execution will matter most next.
Should you buy stock in Biohaven right now?
Before you buy stock in Biohaven, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biohaven wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
